Symposia: Autologous Transplantation: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, autoimmune disorders, AML, Biological therapies, Acute Myeloid Malignancies, Hodgkin lymphoma, epidemiology, Non-Biological therapies, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, Translational Research, CHIP, Clinical Research, Chemotherapy, Plasma Cell Disorders, Combination therapy, health outcomes research, Diseases, Immune Disorders, real-world evidence, Therapies, therapy sequence, Lymphoid Malignancies, Adverse Events, Myeloid Malignancies, Biological Processes, survivorship, Study Population, Human, Minimal Residual Disease , Transplantation
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, autoimmune disorders, AML, Biological therapies, Acute Myeloid Malignancies, Hodgkin lymphoma, epidemiology, Non-Biological therapies, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, Translational Research, CHIP, Clinical Research, Chemotherapy, Plasma Cell Disorders, Combination therapy, health outcomes research, Diseases, Immune Disorders, real-world evidence, Therapies, therapy sequence, Lymphoid Malignancies, Adverse Events, Myeloid Malignancies, Biological Processes, survivorship, Study Population, Human, Minimal Residual Disease , Transplantation
Saturday, December 10, 2022: 9:30 AM-11:00 AM
278-282
(Ernest N. Morial Convention Center)
Moderators:
Aimaz Afrough, MD, University of Texas Southwestern
and
Salomon Manier, MD, PhD, Hopital Huriez Chu Lille
Disclosures:
Manier: AbbVie, Adaptive Biotechnology, Amgen, Celgene/BMS, GlaxoSmithKline, Janssen, Novartis, Oncopeptide, Regeneron, Roche, Takeda: Consultancy.
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:30 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH